Bio-Techne posts Q2 results and declares dividend

Bio-Techne Corporation reported that it issued a press release on February 4, 2026 describing its results of operations for the quarter and six months ended December 31, 2025 and its financial condition as of that date.

Rhea-AI Filing Summary

Bio-Techne Corporation reported that it issued a press release on February 4, 2026 describing its results of operations for the quarter and six months ended December 31, 2025 and its financial condition as of that date. The company also issued a separate press release on the same day announcing a cash dividend, which is attached as another exhibit.

Insights

Equity research analyst

Bio-Techne releases quarterly results details and announces a cash dividend.

Bio-Techne Corporation furnished two press releases dated February 4, 2026. One covers results of operations for the quarter and six months ended December 31, 2025 and the company’s financial condition as of that date.

A second press release announces a cash dividend, signaling continued capital return policy, though the specific amount and key performance metrics are contained in the attached exhibits rather than the main text.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Bio-Techne (TECH) disclose in this 8-K filing?

Bio-Techne disclosed that it issued a press release with its results of operations for the quarter and six months ended December 31, 2025, and financial condition as of that date, plus a separate press release announcing a cash dividend, both dated February 4, 2026.

Which periods do Bio-Techne’s latest results of operations cover?

The results of operations cover Bio-Techne’s quarter and six-month period ended December 31, 2025. The company’s financial condition as of December 31, 2025 is also described in the press release attached as Exhibit 99.1 to this current report.

What dividend action did Bio-Techne (TECH) announce?

Bio-Techne announced a cash dividend in a press release dated February 4, 2026. The announcement is provided as Exhibit 99.2, with the specific dividend details contained in that accompanying press release rather than in the body of this report.

How are Bio-Techne’s earnings and dividend press releases treated legally in this report?

The earnings and dividend press releases are stated as not being deemed “filed” for purposes of Section 18 of the Exchange Act, nor automatically incorporated by reference into Securities Act or Exchange Act filings, unless specifically referenced in another filing.

Which exhibits are attached to Bio-Techne’s February 4, 2026 8-K?

The filing attaches Exhibit 99.1, a press release announcing results of operations dated February 4, 2026, and Exhibit 99.2, a press release announcing a cash dividend dated the same day, along with an Exhibit 104 cover page interactive data file.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 06:30 AM Learn about SEC filing dates

0000842023false00008420232026-02-042026-02-04

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): February 4, 2026

BIO-TECHNE CORPORATION

(Exact Name of Registrant as Specified in its Charter)

​

Minnesota	0-17272	41-1427402
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

​

​

 55413

​

614 McKinley Place NE

Minneapolis, Minnesota 55413

(Address of Principal Executive Offices) (Zip Code)

(612) 379-8854

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TECH	NASDAQ

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

​

☐ Emerging growth company

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 2.02 Results of Operations and Financial Condition

​

A copy of the press release issued by Bio-Techne Corporation on February 4, 2026, describing the results of operations for the quarter and six months ended December 31, 2025, and its financial condition as of December 31, 2025 is attached hereto as Exhibit 99.1.

​

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

​

​

Item 8.01 Other Events

​

A copy of the press release issued by Bio-Techne Corporation on February 4, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.

​

Item 9.01 Financial Statements and Exhibits

​

(d) Exhibits
99.1	Press Release, dated February 4, 2026, announcing results of operations
99.2	Press Release, dated February 4, 2026, announcing cash dividend
​	​
104 -	Cover Page Interactive Data File (embedded within the Inline XBRL document)
​	​

​

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	BIO-TECHNE CORPORATION
​	​
Date: February 4, 2026	By:	/s/ Shane V. Bohnen
​	Shane V. Bohnen
​	Senior Vice President, General Counsel and Secretary

​

​

​

​

​